ArticleNature communications2019
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers.
0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 254 citations in OpenAlex.
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.Translational oncology · 2026Article
- Targeting androgen receptor as a novel radiosensitizing therapy to improve long-term survival and anti-tumor immunity in glioblastoma via TGF-β/Smad3 Axis reprogramming.Cell death discovery · 2026Article
- Quiescent tumor cells shape the immunosuppressive microenvironment in pancreatic cancer.Nature communications · 2026Article
- Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.Journal for immunotherapy of cancer · 2026Article
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.Cancer discovery · 2026Article
- Investigating the Role of Anti-Leukemia Inhibitory Factor Antibody on Cytokine Profile in a Mouse Model of Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Spatial and single-cell characterization of human glioblastoma tumor microenvironment reveals malignant cellular communities.Nature neuroscience · 2026Article
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalk.Nature communications · 2026Article
- VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity.Nature communications · 2026Article
- Tissue IL-6/LIF/LIFR and CXCL9 Expression Correlates with High-Risk NBI Patterns and Squamous Cell Carcinoma in Vocal Fold Lesions.International journal of molecular sciences · 2026Article
- Targeting Androgen Receptor as a Novel Radiosensitizing Therapy to Improve Long-Term Survival and Anti-tumor Immunity in Glioblastoma via TGF-β/Smad3 Axis Reprogramming.Research square · 2026Article
- CXC Chemokine-Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation.MedComm · 2026Review
- Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- Lactic Acid in Tumour Biology.Metabolites · 2026Review
- Tumor-Derived CXCL10 and CCL20 Polarize the Immune Microenvironment in Nasopharyngeal Carcinoma via Competitive Recruitment of Effector T Cells and Tregs.International journal of medical sciences · 2026Article
- Targeting Iron Regulatory Protein 2 in Tumor-associated Macrophages Activates Antitumor Immunity in NSCLC via Modulating SphK1-PD-L1 Axis.International journal of biological sciences · 2026Article
- Clinical significance and oncogenic role of ECHDC2 in glioblastoma: a comprehensive analysis based on bioinformatics andFrontiers in genetics · 2026Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Mónica Pascual-GarcíaVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9768-0641
Ester Bonfill-TeixidorVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Ester Planas-RigolVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Carlota Rubio-PerezVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Raffaella IurlaroVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Alexandra AriasVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Isabel CuartasVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Ada Sala-HojmanVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Laura EscuderoVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7385-673X
Francisco Martínez-RicarteVall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Isabel Huber-RuanoVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Paolo NuciforoVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1380-0990
Leire PedrosaHospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Carolina MarquesSeve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Center, CNIO, 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-8308-5630
Irene BrañaVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Elena GarraldaVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
María VieitoVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Massimo SquatritoSeve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Center, CNIO, 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-4593-3790
Estela PinedaHospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Francesc GrausHospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Carmen EspejoVall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9949-5901
Juan SahuquilloVall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0713-5875
Josep TaberneroVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2495-8139
Joan SeoaneVall d Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain. jseoane@vhio.net.
Vall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESSpanish National Cancer Research Centre · ESInstitució Catalana de Recerca i Estudis Avançats · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer response to immunotherapy depends on the infiltration of CD8
Indexed as
AnimalsAntibodies, NeutralizingCD8-Positive T-LymphocytesChemokine CCL2Chemokine CXCL9Epigenesis, GeneticHumansImmunologic MemoryLeukemia Inhibitory FactorLymphocytes, Tumor-InfiltratingMacrophagesMice, Inbred C57BLMice, SCIDNeoplasmsNeoplasm TransplantationProgrammed Cell Death 1 ReceptorAntibodies, NeutralizingCCL2 protein, humanChemokine CCL2Chemokine CXCL9CXCL9 protein, humanLeukemia Inhibitory FactorPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.